A Phase 4 interventional study of Adalimumab in Moderate to Severe Plaque Psoriasis, sponsored by AbbVie (prior sponsor, Abbott). Completed at 7 sites in Russian Federation. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-10-01.
Sponsored by AbbVie (prior sponsor, Abbott) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 48 studies testing adalimumab in Psoriasis — 6 open to participants now, 6 under way, 1 of them phase 3. Adalimumab · Psoriasis.
Among the 48 studies testing adalimumab in Psoriasis, this one is the 36th largest by enrollment, is one of 4 that started in 2012, is one of 11 in phase 4, and was the 22nd registered.
2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.
Browse Psoriasis studies →6 of the 48 studies testing adalimumab in Psoriasis are open now, in 4 countries. Recruiting first, the newest first:
South Valley University · Sites in Egypt
Ages 18–70 · Healthy volunteers
Mabscale, LLC · Sites in Russian Federation
Ages 18–65
Second Affiliated Hospital, School of Medicine, Zhejiang University · Sites in China
Ages 18–75 · Healthy volunteers
University of California, San Francisco · Sites in United States
Ages 18+
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Ages 4–17
By country, each count listing its studies:
Adalimumab: first FDA approval 2002 (HUMIRA), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →
Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
48 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 6 · Phase 3 27 · Phase 4 11
First in 2003; this study’s year is marked. 4 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 50 is below the median of 75 across 1,567 interventional studies indexed under Psoriasis.
Median enrollment 148 across the 48 interventional studies. Of the 41 that completed or were terminated, 27 (66%) have results posted.
This tab as a report to print or save as PDF → With an account.
34 of 48 have an industry lead sponsor. The 10 most frequent:
This study is registered under AbbVie (prior sponsor, Abbott), one of the names counted as AbbVie. Under that name alone:
AbbVie (prior sponsor, Abbott) is the lead sponsor of 223 studies on the registry; none are open to participants now.
79 studies in Psoriasis by AbbVie: 2 open now, 6 under way, 1 of them phase 3. Of 71 finished, 42 (59%) have results posted.
Among the 79 studies in Psoriasis by AbbVie, this one is the 40th largest by enrollment of the 48 interventional ones that give a count, is one of 3 that started in 2012, is one of 5 in phase 4, and was the 25th registered.
AbbVie’s Psoriasis studies by the year they started, since 2005.
None of the studies under way reaches primary completion within a year.
Among the 48 studies testing adalimumab in Psoriasis, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among AbbVie’s 79 in Psoriasis:
This tab as a report to print or save as PDF → With an account.
This is an open-label study designed to establish the safety and effectiveness of adalimumab in the treatment of moderate to severe plaque psoriasis after 24 weeks of treatment.
During the treatment period, participants will receive an initial adalimumab 80 milligram (mg) subcutaneous (sc) dose, followed by adalimumab 40 mg sc every other week starting one week after initial dose. Safety and effectiveness assessments will be completed at Baseline, Week 2, Week 4, Week 8, Week 12, Week 16 and Week 24. Participants may discontinue adalimumab treatment at any time during study participation. Participants that end study participation early will have a Premature Discontinuation visit. All participants who do not initiate commercial Humira® will have a follow-up phone call 70 days after the last administration of study drug to obtain information on any new or ongoing Adverse Events (AEs). The 70-day follow-up phone call will not be required for any participant that initiates adalimumab therapy not supplied in the context of the clinical trial after the end of study participation.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
A patient will be eligible for study participation if he/she meets the following criteria:
Exclusion Criteria:
Patient who cannot discontinue topical therapies for the treatment of psoriasis such as , vitamin D analogs, or retinoids at least 14 days prior to the Baseline (Week 0) visit and during the study. Participants are allowed to use:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received an initial adalimumab 80 mg subcutaneous dose, followed by adalimumab 40 mg subcutaneous every other week starting one week after the initial dose for up to 24 weeks.
Biological: Adalimumab
Also known as: ABT-D2E7, Humira
Percentage of Participants Achieving a Psoriasis Area and Severity Index 75 (PASI 75) Response at Week 24
The percentage of participants with a ≥ 75% reduction (improvement) in Psoriasis Area and Severity Index (PASI) score from Baseline. PASI is a combination of the intensity of psoriasis, assessed by the erythema (reddening), induration (plaque thickness) and desquamation (scaling) on a scale from no symptoms (0), slight (1), moderate (2), marked (3) or very marked (4), together with the percentage of the area affected, rated on a scale from 0 to 6. PASI scoring is performed at four body areas, the head, arms, trunk, and legs. The total PASI score ranges from 0 to 72. The higher the total score, the more severe the disease.
Time frame: Baseline and Week 24
Percentage of Participants Achieving a Physician's Global Assessment of Clear
The Physician's Global Assessment (PGA) is a 6-point scale used to measure the severity of disease at the time of the qualified investigator's evaluation of the participant. The degree of overall lesion severity was evaluated using the following categories: * 0: No evidence of scaling, erythema, or plaque elevation, overall score of cleared; * 1: Occasional fine scale over \<5% of lesions, faint erythema, minimal plaque elevation, overall score of minimal; * 2: Fine scale dominates, light red coloration, mild plaque elevation, overall score of mild; * 3: Course scale dominates, moderate red coloration, moderate plaque elevation, overall score of moderate; * 4: Thick non-tenacious scale dominates, bright red coloration, marked plaque elevation, overall score of marked; * 5: Very thick tenacious scale predominates, dusky to deep red coloration, severe plaque elevation, overall score of severe. The percentage of participants achieving a PGA score of clear (0) is reported.
Time frame: Weeks 2, 4, 8, 12, 16 and 24
Percentage of Participants Achieving a Physician's Global Assessment of Clear or Minimal
The Physician's Global Assessment (PGA) is a 6-point scale used to measure the severity of disease at the time of the qualified investigator's evaluation of the participant. The degree of overall lesion severity was evaluated using the following categories: * 0: No evidence of scaling, erythema, or plaque elevation, overall score of cleared; * 1: Occasional fine scale over \<5% of lesions, faint erythema, minimal plaque elevation, overall score of minimal; * 2: Fine scale dominates, light red coloration, mild plaque elevation, overall score of mild; * 3: Course scale dominates, moderate red coloration, moderate plaque elevation, overall score of moderate; * 4: Thick non-tenacious scale dominates, bright red coloration, marked plaque elevation, overall score of marked; * 5: Very thick tenacious scale predominates, dusky to deep red coloration, severe plaque elevation, overall score of severe. The percentage of participants achieving a PGA score of clear (0) or minimal (1) is reported.
Time frame: Weeks 2, 4, 8, 12, 16 and 24
Percentage of Participants Achieving a One Grade Improvement in Physician's Global Assessment (PGA)
The PGA is a 6-point scale used to measure the severity of disease at the time of the qualified investigator's evaluation of the participant. The degree of overall lesion severity was evaluated using the following categories: * 0: No evidence of scaling, erythema, or plaque elevation, overall score of cleared; * 1: Occasional fine scale over \<5% of lesions, faint erythema, minimal plaque elevation, overall score of minimal; * 2: Fine scale dominates, light red coloration, mild plaque elevation, overall score of mild; * 3: Course scale dominates, moderate red coloration, moderate plaque elevation, overall score of moderate; * 4: Thick non-tenacious scale dominates, bright red coloration, marked plaque elevation, overall score of marked; * 5: Very thick tenacious scale predominates, dusky to deep red coloration, severe plaque elevation, overall score of severe. The percentage of participants achieving a shift from Baseline to a less severe category is reported.
Time frame: Baseline and Weeks 2, 4, 8, 12, 16 and 24
Percentage of Participants Achieving a PASI 50 Response
The percentage of participants with a ≥ 50% reduction (improvement) in Psoriasis Area and Severity Index (PASI) score from Baseline. PASI is a combination of the intensity of psoriasis, assessed by the erythema (reddening), induration (plaque thickness) and desquamation (scaling) on a scale from no symptoms (0), slight (1), moderate (2), marked (3) or very marked (4), together with the percentage of the area affected, rated on a scale from 0 to 6. PASI scoring is performed at four body areas, the head, arms, trunk, and legs. The total PASI score ranges from 0 to 72. The higher the total score, the more severe the disease.
Time frame: Baseline and Weeks 2, 4, 8, 12, 16, and 24
Percentage of Participants Achieving a PASI 75 Response
The percentage of participants with a ≥ 75% reduction (improvement) in Psoriasis Area and Severity Index (PASI) score from Baseline. PASI is a combination of the intensity of psoriasis, assessed by the erythema (reddening), induration (plaque thickness) and desquamation (scaling) on a scale from no symptoms (0), slight (1), moderate (2), marked (3) or very marked (4), together with the percentage of the area affected, rated on a scale from 0 to 6. PASI scoring is performed at four body areas, the head, arms, trunk, and legs. The total PASI score ranges from 0 to 72. The higher the total score, the more severe the disease.
Time frame: Baseline and Weeks 2, 4, 8, 12, and 16
Percentage of Participants Achieving a PASI 90 Response
The percentage of participants with a ≥ 90% reduction (improvement) in Psoriasis Area and Severity Index (PASI) score from Baseline. PASI is a combination of the intensity of psoriasis, assessed by the erythema (reddening), induration (plaque thickness) and desquamation (scaling) on a scale from no symptoms (0), slight (1), moderate (2), marked (3) or very marked (4), together with the percentage of the area affected, rated on a scale from 0 to 6. PASI scoring is performed at four body areas, the head, arms, trunk, and legs. The total PASI score ranges from 0 to 72. The higher the total score, the more severe the disease.
Time frame: Baseline and Weeks 2, 4, 8, 12, 16, and 24
Percentage of Participants Achieving a PASI 100 Response
The percentage of participants with a 100% reduction (improvement) in Psoriasis Area and Severity Index (PASI) score from Baseline. PASI is a combination of the intensity of psoriasis, assessed by the erythema (reddening), induration (plaque thickness) and desquamation (scaling) on a scale from no symptoms (0), slight (1), moderate (2), marked (3) or very marked (4), together with the percentage of the area affected, rated on a scale from 0 to 6. PASI scoring is performed at four body areas, the head, arms, trunk, and legs. The total PASI score ranges from 0 to 72. The higher the total score, the more severe the disease.
Time frame: Baseline and Weeks 2, 4, 8, 12, 16, and 24
Percent Change From Baseline in Psoriasis Area and Severity Index (PASI) Score
PASI is a combination of the intensity of psoriasis, assessed by the erythema (reddening), induration (plaque thickness) and desquamation (scaling) on a scale from no symptoms (0), slight (1), moderate (2), marked (3) or very marked (4), together with the percentage of the area affected, rated on a scale from 0 to 6. PASI scoring is performed at four body areas, the head, arms, trunk, and legs. The total PASI score ranges from 0 to 72. The higher the total score, the more severe the disease. Change from Baseline is presented as a percentage of the Baseline value: Post-baseline value - Baseline value / Baseline value \* 100. A negative change from Baseline indicates improvement.
Time frame: Baseline and Weeks 2, 4, 8, 12, 16, and 24
Percent Change From Baseline in Dermatology Life Quality Index (DLQI)
The DLQI questionnaire asks participants to evaluate the degree that psoriasis has affected their quality of life in the last week, and includes the following parameters: symptoms and feelings, daily activities, leisure activities, work or school activities, personal relationships and treatment related feelings. Participants answer 10 questions on a scale from 0 (not at all) to 3 (very much); the range of the total score is 0 to 30. A score of 21 to 30 means an extremely large effect on the participant's life whereas 0-1 means that the disease has no effect at all. Change from Baseline is presented as a percentage of the Baseline value: Post-baseline value - Baseline value / Baseline value \* 100. A negative change from Baseline indicates improvement.
Time frame: Baseline and Weeks 8, 12, and 24
Percent Change From Baseline in Nail Psoriasis Severity Index (NAPSI)
NAPSI grades nails for both nail matrix psoriasis and nail bed psoriasis. The most affected fingernail was determined at Baseline and used for the analysis. Nail matrix psoriasis consists of any of the following: pitting, leukonychia, red spots in the lunula, or nail plate crumbling. Nail bed psoriasis is the presence or absence of onycholysis, splinter hemorrhages, oil drop (salman patch) discoloration or nail bed hyperkeratosis. Scoring for each is based on the following scale: * 0 = none; * 1 = present in 1/4 nail quadrants; * 2 = present in 2/4 nail quadrants; * 3 = present in 3/4 nail quadrants; * 4 = present in 4/4 nail quadrants. The sum of these two scores is the total score for the nail, and ranges from 0 (no nail psoriasis) to 8 (psoriasis in 4/4 nail quadrants). Change from Baseline is presented as a percentage of the Baseline value, calculated as: Week 24 value - Baseline value / Baseline value \* 100. A negative change from Baseline indicates improvement.
Time frame: Baseline and Week 24
Change From Baseline in Hemoglobin
Safety variables included laboratory data, vital signs and adverse events.
Time frame: Baseline and Week 24 (or Early Termination Visit)
Change From Baseline in Hematocrit
Safety variables included laboratory data, vital signs and adverse events. The hematocrit measures the volume of red blood cells compared to the total blood volume (red blood cells and plasma).
Time frame: Baseline and Week 24 (or Early Termination Visit)
Change From Baseline in Red Blood Cell Count
Safety variables included laboratory data, vital signs and adverse events.
Time frame: Baseline and Week 24 (or Early Termination Visit)
Change From Baseline in Blood Cell Counts
Safety variables included laboratory data, vital signs and adverse events.
Time frame: Baseline and Week 24 (or Early Termination Visit)
Change From Baseline in Erythrocyte Sedimentation Rate
Safety variables included laboratory data, vital signs and adverse events.
Time frame: Baseline and Week 24 (or Early Termination Visit)
Change From Baseline in Alanine Aminotransferase
Safety variables included laboratory data, vital signs and adverse events.
Time frame: Baseline and Week 24 (or Early Termination Visit)
Change From Baseline in Aspartate Aminotransferase
Safety variables included laboratory data, vital signs and adverse events.
Time frame: Baseline and Week 24 (or Early Termination Visit)
Change From Baseline in Alkaline Phosphatase
Safety variables included laboratory data, vital signs and adverse events.
Time frame: Baseline and Week 24 (or Early Termination Visit)
Change From Baseline in Total Bilirubin
Safety variables included laboratory data, vital signs and adverse events.
Time frame: Baseline and Week 24 (or Early Termination Visit)
Change From Baseline in Creatinine
Safety variables included laboratory data, vital signs and adverse events.
Time frame: Baseline and Week 24 (or Early Termination Visit)
Change From Baseline in Blood Urea Nitrogen (BUN)
Safety variables included laboratory data, vital signs and adverse events.
Time frame: Baseline and Week 24 (or Early Termination Visit)
Change From Baseline in Uric Acid
Safety variables included laboratory data, vital signs and adverse events.
Time frame: Baseline and Week 24 (or Early Termination Visit)
Change From Baseline in Inorganic Phosphate
Safety variables included laboratory data, vital signs and adverse events.
Time frame: Baseline and Week 24 (or Early Termination Visit)
Change From Baseline in Calcium, Sodium and Potassium
Safety variables included laboratory data, vital signs and adverse events.
Time frame: Baseline and Week 24 (or Early Termination Visit)
Change From Baseline in Glucose
Safety variables included laboratory data, vital signs and adverse events.
Time frame: Baseline and Week 24 (or Early Termination Visit)
Change From Baseline in Albumin
Safety variables included laboratory data, vital signs and adverse events.
Time frame: Baseline and Week 24 (or Early Termination Visit)
Change From Baseline in Total Protein
Safety variables included laboratory data, vital signs and adverse events.
Time frame: Baseline and Week 24 (or Early Termination Visit)
Change From Baseline in Cholesterol
Safety variables included laboratory data, vital signs and adverse events.
Time frame: Baseline and Week 24 (or Early Termination Visit)
Change From Baseline in Triglycerides
Safety variables included laboratory data, vital signs and adverse events.
Time frame: Baseline and Week 24 (or Early Termination Visit)
Change From Baseline in High Sensitivity C-reactive Protein (hsCRP)
Safety variables included laboratory data, vital signs and adverse events.
Time frame: Baseline and Week 24 (or Early Termination Visit)
Change From Baseline in Urine pH
Safety variables included laboratory data, vital signs and adverse events.
Time frame: Baseline and Week 24 (or Early Termination Visit)
Change From Baseline in Urine Specific Gravity
Safety variables included laboratory data, vital signs and adverse events. Specific gravity is a measure of the amount of material dissolved in the urine. Specific gravity is the ratio of the density (mass of a unit volume) of a substance to the density (mass of the same unit volume) of a reference substance.
Time frame: Baseline and Week 24 (or Early Termination Visit)
Change From Baseline in Blood Pressure
Safety variables included laboratory data, vital signs and adverse events.
Time frame: Baseline and Week 24 (or Early Termination Visit)
Change From Baseline in Pulse
Safety variables included laboratory data, vital signs and adverse events.
Time frame: Baseline and Week 24 (or Early Termination Visit)
Change From Baseline in Respiratory Rate
Safety variables included laboratory data, vital signs and adverse events.
Time frame: Baseline and Week 24 (or Early Termination Visit)
Change From Baseline in Weight
Safety variables included laboratory data, vital signs and adverse events.
Time frame: Baseline and Week 24 (or Early Termination Visit)
Change From Baseline in Body Temperature
Safety variables included laboratory data, vital signs and adverse events.
Time frame: Baseline and Week 24 (or Early Termination Visit)
Number of Participants With Adverse Events (AEs)
An AE is any untoward medical occurrence, which does not necessarily have a causal relationship with treatment. The investigator rated the severity of each AE as either: Mild: The AE is transient and easily tolerated; Moderate: The AE causes the participant discomfort and interrupts usual activities. Severe: The AE causes considerable interference with usual activities and may be incapacitating or life-threatening. A serious adverse event (SAE) is an AE that results in death, is life-threatening, results in or prolongs hospitalization, results in congenital anomaly, persistent or significant disability/incapacity, spontaneous or elective abortion, or requires intervention to prevent a serious outcome. Drug-related AEs are those assessed by the investigator as either probably or possibly related. Other malignancy excludes lymphoma, hepatosplenic T-cell lymphoma (HSTCL), leukemia, non-melanoma skin cancer (NMSC), and melanoma.
Time frame: From the first dose of study drug until 70 days after the last dose (up to 33 weeks).
| Milestone | Adalimumab |
|---|---|
| Started | 50 |
| Completed | 50 |
| Not completed | 0 |
The percentage of participants with a ≥ 75% reduction (improvement) in Psoriasis Area and Severity Index (PASI) score from Baseline. PASI is a combination of the intensity of psoriasis, assessed by the erythema (reddening), induration (plaque thickness) and desquamation (scaling) on a scale from no symptoms (0), slight (1), moderate (2), marked (3) or very marked (4), together with the percentage of the area affected, rated on a scale from 0 to 6. PASI scoring is performed at four body areas, the head, arms, trunk, and legs. The total PASI score ranges from 0 to 72. The higher the total score, the more severe the disease.
| percentage of participants | Adalimumab |
|---|---|
| Percentage of Participants Achieving a Psoriasis Area and Severity Index 75 (PASI 75) Response at Week 24 | 82.0 |
Safety variables included laboratory data, vital signs and adverse events.
| g/L | Adalimumab |
|---|---|
| Change From Baseline in Hemoglobin | 0.6 ± 9.75 |
Safety variables included laboratory data, vital signs and adverse events. The hematocrit measures the volume of red blood cells compared to the total blood volume (red blood cells and plasma).
| liters/liter | Adalimumab |
|---|---|
| Change From Baseline in Hematocrit | 0.007 ± 0.0348 |
Safety variables included laboratory data, vital signs and adverse events.
| × 10^12 cells/L | Adalimumab |
|---|---|
| Change From Baseline in Red Blood Cell Count | 0.02 ± 0.352 |
The Physician's Global Assessment (PGA) is a 6-point scale used to measure the severity of disease at the time of the qualified investigator's evaluation of the participant. The degree of overall lesion severity was evaluated using the following categories: * 0: No evidence of scaling, erythema, or plaque elevation, overall score of cleared; * 1: Occasional fine scale over \<5% of lesions, faint erythema, minimal plaque elevation, overall score of minimal; * 2: Fine scale dominates, light red coloration, mild plaque elevation, overall score of mild; * 3: Course scale dominates, moderate red coloration, moderate plaque elevation, overall score of moderate; * 4: Thick non-tenacious scale dominates, bright red coloration, marked plaque elevation, overall score of marked; * 5: Very thick tenacious scale predominates, dusky to deep red coloration, severe plaque elevation, overall score of severe. The percentage of participants achieving a PGA score of clear (0) is reported.
| percentage of participants | Adalimumab |
|---|---|
| Week 2 | 0 |
| Week 4 | 0 |
| Week 8 | 6.0 |
| Week 12 | 20.0 |
| Week 16 | 60.0 |
| Week 24 | 70.0 |
The Physician's Global Assessment (PGA) is a 6-point scale used to measure the severity of disease at the time of the qualified investigator's evaluation of the participant. The degree of overall lesion severity was evaluated using the following categories: * 0: No evidence of scaling, erythema, or plaque elevation, overall score of cleared; * 1: Occasional fine scale over \<5% of lesions, faint erythema, minimal plaque elevation, overall score of minimal; * 2: Fine scale dominates, light red coloration, mild plaque elevation, overall score of mild; * 3: Course scale dominates, moderate red coloration, moderate plaque elevation, overall score of moderate; * 4: Thick non-tenacious scale dominates, bright red coloration, marked plaque elevation, overall score of marked; * 5: Very thick tenacious scale predominates, dusky to deep red coloration, severe plaque elevation, overall score of severe. The percentage of participants achieving a PGA score of clear (0) or minimal (1) is reported.
| percentage of participants | Adalimumab |
|---|---|
| Week 2 | 2.0 |
| Week 4 | 12.0 |
| Week 8 | 34.0 |
| Week 12 | 72.0 |
| Week 16 | 86.0 |
| Week 24 | 80.0 |
The PGA is a 6-point scale used to measure the severity of disease at the time of the qualified investigator's evaluation of the participant. The degree of overall lesion severity was evaluated using the following categories: * 0: No evidence of scaling, erythema, or plaque elevation, overall score of cleared; * 1: Occasional fine scale over \<5% of lesions, faint erythema, minimal plaque elevation, overall score of minimal; * 2: Fine scale dominates, light red coloration, mild plaque elevation, overall score of mild; * 3: Course scale dominates, moderate red coloration, moderate plaque elevation, overall score of moderate; * 4: Thick non-tenacious scale dominates, bright red coloration, marked plaque elevation, overall score of marked; * 5: Very thick tenacious scale predominates, dusky to deep red coloration, severe plaque elevation, overall score of severe. The percentage of participants achieving a shift from Baseline to a less severe category is reported.
| percentage of participants | Adalimumab |
|---|---|
| Week 2 | 40.0 |
| Week 4 | 74.0 |
| Week 8 | 98.0 |
| Week 12 | 98.0 |
| Week 16 | 100 |
| Week 24 | 96.0 |
The percentage of participants with a ≥ 50% reduction (improvement) in Psoriasis Area and Severity Index (PASI) score from Baseline. PASI is a combination of the intensity of psoriasis, assessed by the erythema (reddening), induration (plaque thickness) and desquamation (scaling) on a scale from no symptoms (0), slight (1), moderate (2), marked (3) or very marked (4), together with the percentage of the area affected, rated on a scale from 0 to 6. PASI scoring is performed at four body areas, the head, arms, trunk, and legs. The total PASI score ranges from 0 to 72. The higher the total score, the more severe the disease.
| percentage of participants | Adalimumab |
|---|---|
| Week 2 | 8.0 |
| Week 4 | 36.0 |
| Week 8 | 84.0 |
| Week 12 | 88.0 |
| Week 16 | 94.0 |
| Week 24 | 96.0 |
The percentage of participants with a ≥ 75% reduction (improvement) in Psoriasis Area and Severity Index (PASI) score from Baseline. PASI is a combination of the intensity of psoriasis, assessed by the erythema (reddening), induration (plaque thickness) and desquamation (scaling) on a scale from no symptoms (0), slight (1), moderate (2), marked (3) or very marked (4), together with the percentage of the area affected, rated on a scale from 0 to 6. PASI scoring is performed at four body areas, the head, arms, trunk, and legs. The total PASI score ranges from 0 to 72. The higher the total score, the more severe the disease.
| percentage of participants | Adalimumab |
|---|---|
| Week 2 | 0 |
| Week 4 | 4.0 |
| Week 8 | 44.0 |
| Week 12 | 76.0 |
| Week 16 | 82.0 |
The percentage of participants with a ≥ 90% reduction (improvement) in Psoriasis Area and Severity Index (PASI) score from Baseline. PASI is a combination of the intensity of psoriasis, assessed by the erythema (reddening), induration (plaque thickness) and desquamation (scaling) on a scale from no symptoms (0), slight (1), moderate (2), marked (3) or very marked (4), together with the percentage of the area affected, rated on a scale from 0 to 6. PASI scoring is performed at four body areas, the head, arms, trunk, and legs. The total PASI score ranges from 0 to 72. The higher the total score, the more severe the disease.
| percentage of participants | Adalimumab |
|---|---|
| Week 2 | 0 |
| Week 4 | 0 |
| Week 8 | 20.0 |
| Week 12 | 48.0 |
| Week 16 | 72.0 |
| Week 24 | 76.0 |
The percentage of participants with a 100% reduction (improvement) in Psoriasis Area and Severity Index (PASI) score from Baseline. PASI is a combination of the intensity of psoriasis, assessed by the erythema (reddening), induration (plaque thickness) and desquamation (scaling) on a scale from no symptoms (0), slight (1), moderate (2), marked (3) or very marked (4), together with the percentage of the area affected, rated on a scale from 0 to 6. PASI scoring is performed at four body areas, the head, arms, trunk, and legs. The total PASI score ranges from 0 to 72. The higher the total score, the more severe the disease.
| percentage of participants | Adalimumab |
|---|---|
| Week 2 | 0 |
| Week 4 | 0 |
| Week 8 | 2.0 |
| Week 12 | 20.0 |
| Week 16 | 50.0 |
| Week 24 | 64.0 |
PASI is a combination of the intensity of psoriasis, assessed by the erythema (reddening), induration (plaque thickness) and desquamation (scaling) on a scale from no symptoms (0), slight (1), moderate (2), marked (3) or very marked (4), together with the percentage of the area affected, rated on a scale from 0 to 6. PASI scoring is performed at four body areas, the head, arms, trunk, and legs. The total PASI score ranges from 0 to 72. The higher the total score, the more severe the disease. Change from Baseline is presented as a percentage of the Baseline value: Post-baseline value - Baseline value / Baseline value \* 100. A negative change from Baseline indicates improvement.
| percent change | Adalimumab |
|---|---|
| Week 2 | -20.42 ± 15.586 |
| Week 4 | -45.75 ± 17.444 |
| Week 8 | -69.28 ± 20.759 |
| Week 12 | -81.74 ± 25.039 |
| Week 16 | -89.42 ± 19.789 |
| Week 24 | -91.18 ± 16.579 |
The DLQI questionnaire asks participants to evaluate the degree that psoriasis has affected their quality of life in the last week, and includes the following parameters: symptoms and feelings, daily activities, leisure activities, work or school activities, personal relationships and treatment related feelings. Participants answer 10 questions on a scale from 0 (not at all) to 3 (very much); the range of the total score is 0 to 30. A score of 21 to 30 means an extremely large effect on the participant's life whereas 0-1 means that the disease has no effect at all. Change from Baseline is presented as a percentage of the Baseline value: Post-baseline value - Baseline value / Baseline value \* 100. A negative change from Baseline indicates improvement.
| percent change | Adalimumab |
|---|---|
| Week 8 | -60.04 ± 40.435 |
| Week 12 | -75.03 ± 45.311 |
| Week 24 | -79.16 ± 34.784 |
NAPSI grades nails for both nail matrix psoriasis and nail bed psoriasis. The most affected fingernail was determined at Baseline and used for the analysis. Nail matrix psoriasis consists of any of the following: pitting, leukonychia, red spots in the lunula, or nail plate crumbling. Nail bed psoriasis is the presence or absence of onycholysis, splinter hemorrhages, oil drop (salman patch) discoloration or nail bed hyperkeratosis. Scoring for each is based on the following scale: * 0 = none; * 1 = present in 1/4 nail quadrants; * 2 = present in 2/4 nail quadrants; * 3 = present in 3/4 nail quadrants; * 4 = present in 4/4 nail quadrants. The sum of these two scores is the total score for the nail, and ranges from 0 (no nail psoriasis) to 8 (psoriasis in 4/4 nail quadrants). Change from Baseline is presented as a percentage of the Baseline value, calculated as: Week 24 value - Baseline value / Baseline value \* 100. A negative change from Baseline indicates improvement.
| percent change | Adalimumab |
|---|---|
| Percent Change From Baseline in Nail Psoriasis Severity Index (NAPSI) | -68.06 ± 34.134 |
Safety variables included laboratory data, vital signs and adverse events.
| × 10^9 cells/L | Adalimumab |
|---|---|
| Platelets | -9.8 ± 55.51 |
| White blood cells | 0.00 ± 2.248 |
| Neutrophils | -0.446 ± 2.1341 |
| Lymphocytes | 0.468 ± 0.6196 |
| Monocytes | 0.006 ± 0.1992 |
| Eosinophils | -0.036 ± 0.2905 |
| Basophils | 0.013 ± 0.0602 |
Safety variables included laboratory data, vital signs and adverse events.
| mm/hour | Adalimumab |
|---|---|
| Change From Baseline in Erythrocyte Sedimentation Rate | -4.087 ± 9.8744 |
Safety variables included laboratory data, vital signs and adverse events.
| U/L | Adalimumab |
|---|---|
| Change From Baseline in Alanine Aminotransferase | 2.8 ± 28.95 |
Safety variables included laboratory data, vital signs and adverse events.
| U/L | Adalimumab |
|---|---|
| Change From Baseline in Aspartate Aminotransferase | 1.5 ± 16.81 |
Safety variables included laboratory data, vital signs and adverse events.
| U/L | Adalimumab |
|---|---|
| Change From Baseline in Alkaline Phosphatase | -4.7 ± 14.84 |
Safety variables included laboratory data, vital signs and adverse events.
| µmol/L | Adalimumab |
|---|---|
| Change From Baseline in Total Bilirubin | 0.5 ± 4.83 |
Safety variables included laboratory data, vital signs and adverse events.
| µmol/L | Adalimumab |
|---|---|
| Change From Baseline in Creatinine | 2.1 ± 9.40 |
Safety variables included laboratory data, vital signs and adverse events.
| mmol/L | Adalimumab |
|---|---|
| Change From Baseline in Blood Urea Nitrogen (BUN) | 0.42 ± 1.521 |
Safety variables included laboratory data, vital signs and adverse events.
| µmol/L | Adalimumab |
|---|---|
| Change From Baseline in Uric Acid | -1.8 ± 66.52 |
Safety variables included laboratory data, vital signs and adverse events.
| mmol/L | Adalimumab |
|---|---|
| Change From Baseline in Inorganic Phosphate | 0.061 ± 0.1900 |
Safety variables included laboratory data, vital signs and adverse events.
| mmol/L | Adalimumab |
|---|---|
| Calcium | 0.005 ± 0.1035 |
| Sodium | -0.8 ± 2.30 |
| Potassium | 0.00 ± 0.435 |
Safety variables included laboratory data, vital signs and adverse events.
| mmol/L | Adalimumab |
|---|---|
| Change From Baseline in Glucose | 0.12 ± 0.887 |
Safety variables included laboratory data, vital signs and adverse events.
| g/L | Adalimumab |
|---|---|
| Change From Baseline in Albumin | 0.1 ± 2.87 |
Safety variables included laboratory data, vital signs and adverse events.
| g/L | Adalimumab |
|---|---|
| Change From Baseline in Total Protein | -0.4 ± 3.91 |
Safety variables included laboratory data, vital signs and adverse events.
| mmol/L | Adalimumab |
|---|---|
| Change From Baseline in Cholesterol | 0.045 ± 0.7723 |
Safety variables included laboratory data, vital signs and adverse events.
| mmol/L | Adalimumab |
|---|---|
| Change From Baseline in Triglycerides | 0.194 ± 1.0007 |
Safety variables included laboratory data, vital signs and adverse events.
| mg/L | Adalimumab |
|---|---|
| Change From Baseline in High Sensitivity C-reactive Protein (hsCRP) | -2.443 ± 5.2543 |
Safety variables included laboratory data, vital signs and adverse events.
| pH units | Adalimumab |
|---|---|
| Change From Baseline in Urine pH | 0.14 ± 0.663 |
Safety variables included laboratory data, vital signs and adverse events. Specific gravity is a measure of the amount of material dissolved in the urine. Specific gravity is the ratio of the density (mass of a unit volume) of a substance to the density (mass of the same unit volume) of a reference substance.
| ratio | Adalimumab |
|---|---|
| Change From Baseline in Urine Specific Gravity | 0.0003 ± 0.00792 |
Safety variables included laboratory data, vital signs and adverse events.
| mm Hg | Adalimumab |
|---|---|
| Systolic blood pressure | 0.9 ± 8.13 |
| Diastolic blood pressure | -0.4 ± 7.03 |
Safety variables included laboratory data, vital signs and adverse events.
| beats per minute | Adalimumab |
|---|---|
| Change From Baseline in Pulse | 0.2 ± 4.05 |
Safety variables included laboratory data, vital signs and adverse events.
| respirations per minute | Adalimumab |
|---|---|
| Change From Baseline in Respiratory Rate | -0.0 ± 1.33 |
Safety variables included laboratory data, vital signs and adverse events.
| kg | Adalimumab |
|---|---|
| Change From Baseline in Weight | -0.18 ± 2.883 |
Safety variables included laboratory data, vital signs and adverse events.
| degrees celsius | Adalimumab |
|---|---|
| Change From Baseline in Body Temperature | -0.03 ± 0.191 |
An AE is any untoward medical occurrence, which does not necessarily have a causal relationship with treatment. The investigator rated the severity of each AE as either: Mild: The AE is transient and easily tolerated; Moderate: The AE causes the participant discomfort and interrupts usual activities. Severe: The AE causes considerable interference with usual activities and may be incapacitating or life-threatening. A serious adverse event (SAE) is an AE that results in death, is life-threatening, results in or prolongs hospitalization, results in congenital anomaly, persistent or significant disability/incapacity, spontaneous or elective abortion, or requires intervention to prevent a serious outcome. Drug-related AEs are those assessed by the investigator as either probably or possibly related. Other malignancy excludes lymphoma, hepatosplenic T-cell lymphoma (HSTCL), leukemia, non-melanoma skin cancer (NMSC), and melanoma.
| participants | Adalimumab |
|---|---|
| Any adverse event | 14 |
| Serious adverse event | 0 |
| AE leading to discontinuation of study drug | 0 |
| Severe adverse event | 0 |
| Drug-related adverse event | 9 |
| Adverse event leading to death | 0 |
| Any infection | 7 |
| Any serious infection | 0 |
| Any opportunistic infection | 0 |
| Latent tuberculosis | 4 |
| Any lymphoma | 0 |
| Any non-melanoma skin cancer | 0 |
| Any other malignancy | 0 |
| Any demyelinating disorder | 0 |
Collected over From the first dose of study drug until 70 days after the last dose (up to 33 weeks).. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Adalimumab | — | 0/50 (0%) | 14/50 (28%) |
| Event | Adalimumab |
|---|---|
| LATENT TUBERCULOSISInfections and infestations | 4/50 |
| RHINITISInfections and infestations | 3/50 |
| ANAEMIABlood and lymphatic system disorders | 1/50 |
| FURUNCLEInfections and infestations | 1/50 |
| HERPES SIMPLEXInfections and infestations | 1/50 |
| ORAL HERPESInfections and infestations | 1/50 |
| RESPIRATORY TRACT INFECTIONInfections and infestations | 1/50 |
| CONTUSIONInjury, poisoning and procedural complications | 1/50 |
| EXCORIATIONInjury, poisoning and procedural complications | 1/50 |
| ALANINE AMINOTRANSFERASE INCREASEDInvestigations | 1/50 |
Intent-to-treat population, defined as all enrolled participants who received at least 1 dose of adalimumab.
| Age, Continuous(years) | Adalimumab |
|---|---|
| Mean | 41.5 ± 9.86 |
| Sex: Female, Male(Participants) | Adalimumab |
|---|---|
| Female | 14 |
| Male | 36 |
| Region of Enrollment(participants) | Adalimumab |
|---|---|
| Russian Federation | 50 |
The record gives a start of May 2012, a primary completion of Sep 2013 and a completion of Sep 2013. It does not say whether these dates are actual or estimated.
Results were first posted in Sep 2014, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Adalimumab
AbbVie (prior sponsor, Abbott) →